From WisPolitics.com/WisBusiness.com …
— At least 2 million cancer patients have now used Exact Sciences’ Oncotype DX Breast Recurrence Score test, the company announced.
The test was created more than 20 years ago by Genomic Health, a California firm that is now a subsidiary of Exact Sciences after it was acquired in 2019 in a $2.8 billion deal.
Of the 2 million cancer patients that have used the test, Exact Sciences says it has helped 1.6 million patients avoiding “potentially unnecessary” treatment. The company says use of the Oncotype DX test has “resulted in average lifetime savings of approximately $10,000 per patient in the U.S. healthcare system” based on an economic analysis.
The test is used to guide treatment for patients with certain early-stage forms of breast cancer, based on personalized genetic assessment. Exact Sciences says it’s the only test of its kind that can predict distant recurrence risk as well as potential chemotherapy benefit.
Brian Baranick, the company’s general manager of precision oncology, says the test has helped “move breast cancer care beyond a one-size-fits-all treatment decision” by supporting patient decisions about their own cancer treatment.
“We’re proud of the test’s ongoing impact on precision oncology worldwide,” he said in a statement.
See the release below.
For more of the latest news on the state economy and Wisconsin businesses from startups to industry leaders, sign up today for a free two-week trial of the daily morning news report from WisBusiness.com.
Sign up here.
Top Stories
– Illinois joins WHO’s global disease network
– South Carolina measles vaccinations jump in January, fueled by surge in Spartanburg County
– Several fall ‘deathly ill’ from suspected Las Vegas bio lab
– Congress Reins In Drug Middlemen in Effort to Lower Prescription Prices
– More Americans are picking higher-deductible Obamacare plans, possibly risking their health
– When the Doctor Needs a Checkup
Press Releases
– Exact Sciences: Oncotype DX Breast Recurrence Score® test surpasses 2 million patients worldwide
